0001140361-19-020720.txt : 20191115 0001140361-19-020720.hdr.sgml : 20191115 20191115172007 ACCESSION NUMBER: 0001140361-19-020720 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20191115 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20191115 DATE AS OF CHANGE: 20191115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 191225353 BUSINESS ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 8-K 1 form8k.htm CURRENT REPORT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K


CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): November 15, 2019
 
BRISTOL-MYERS SQUIBB COMPANY
(Exact name of registrant as specified in its charter)


Delaware
001-01136
22-0790350
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification Number)

430 East 29th Street, 14th Floor
New York, NY, 10016
(Address of Principal Executive Office)

Registrant’s telephone number, including area code: (212) 546-4000


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☒
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.10 Par Value
BMY
New York Stock Exchange
1.000% Notes due 2025
BMY 25
New York Stock Exchange
1.750% Notes due 2035
BMY 35
New York Stock Exchange

 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Item 8.01
Other Events.

FTC Approval

On November 15, 2019, the Federal Trade Commission (“FTC”) accepted a proposed consent order that allows Bristol-Myers Squibb Company’s (“Bristol-Myers Squibb”) pending merger (the “Merger”) with Celgene Corporation (“Celgene”) to proceed, subject to certain conditions, including closing the previously announced divestiture of Celgene’s OTEZLA® (apremilast) business to Amgen Inc. within 10 days following the completion of the Merger.

As a result of the FTC’s acceptance of the consent order, all regulatory approvals required for the consummation of the Merger have been obtained.  Bristol-Myers Squibb and Celgene expect to close the Merger on November 20, 2019 (“Closing Date”).

On November 15, 2019, Bristol-Myers Squibb issued a press release announcing that all required regulatory approvals necessary to complete the Merger have been obtained and the anticipated closing date of the Merger of November 20, 2019.  A copy of this press release is filed pursuant to this Item 8.01 as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein in its entirety.

Extension of Exchange Offers

On November 15, 2019, Bristol-Myers Squibb issued a press release (“Expiration Press Release”) announcing that it currently expects no further extensions of the expiration date of its previously announced (i) offers to exchange (the “Exchange Offers”) notes (the “Celgene Notes”) issued by Celgene for up to $19,850,000,000 aggregate principal amount of new notes issued by Bristol-Myers Squibb and cash and (ii) related solicitations of consents (each, a “Consent Solicitation” and, collectively, the “Consent Solicitations”) to adopt certain amendments (the “Amendments”) that would eliminate substantially all restrictive covenants and certain events of default and other provisions in each of the indentures governing the Celgene Notes. As previously announced, the Exchange Offers and Consent Solicitations are currently scheduled to expire at 5:00 p.m., New York City time, on November 20, 2019 (the “Expiration Date”). Bristol-Myers Squibb currently expects that there will be no further extensions of the Expiration Date as it is anticipated that the Merger will be completed on the Expiration Date.

The Exchange Offers and Consent Solicitations were commenced in connection with the Merger and are being made solely pursuant to the terms and subject to the conditions set forth in the confidential offering memorandum and consent solicitation statement dated April 17, 2019 and the related letter of transmittal, each as amended by the press releases dated May 1, 2019, May 24, 2019, June 28, 2019, September 23, 2019, October 8, 2019, October 18, 2019, October 30, 2019, November 1, 2019, November 5, 2019, November 7, 2019, November 12, 2019 and November 15, 2019, in a private offering exempt from, or not subject to, registration under the Securities Act of 1933, as amended. The Exchange Offers and Consent Solicitations are conditioned upon the closing of the Merger, which condition may not be waived by Bristol-Myers Squibb, and certain other conditions that may be waived by Bristol-Myers Squibb.

The settlement date of the Exchange Offers and Consent Solicitations is expected to occur on November 22, 2019. Supplemental indentures effecting the Amendments relating to the Celgene Notes were executed on May 1, 2019. Such supplemental indentures will become operative upon the settlement date of the Exchange Offers.

A copy of the Expiration Press Release is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein in its entirety.

Important Information For Investors And Stockholders
 
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectus equivalent document. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

In connection with the proposed transaction between Bristol-Myers Squibb and Celgene, on February 1, 2019, Bristol-Myers Squibb filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4, as amended on February 1, 2019 and February 20, 2019, containing a joint proxy statement of Bristol-Myers Squibb and Celgene that also constitutes a prospectus of Bristol-Myers Squibb. The registration statement was declared effective by the SEC on February 22, 2019, Bristol Myers Squibb and Celgene commenced mailing the definitive joint proxy statement/prospectus to stockholders of Bristol-Myers Squibb and Celgene on or about February 22, 2019, and the special meetings of the stockholders of Bristol-Myers Squibb and Celgene were held on April 12, 2019. INVESTORS AND SECURITY HOLDERS OF BRISTOL-MYERS SQUIBB AND CELGENE ARE URGED TO READ THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION.  Investors and security holders will be able to obtain free copies of the registration statement and the definitive joint proxy statement/prospectus and other documents filed with the SEC by Bristol-Myers Squibb or Celgene through the website maintained by the SEC at http://www.sec.gov.  Copies of the documents filed with the SEC by Bristol Myers Squibb are available free of charge on Bristol-Myers Squibb’s internet website at http://www.bms.com under the tab, “Investors” and under the heading “Financial Reporting” and subheading “SEC Filings” or by contacting Bristol-Myers Squibb’s Investor Relations Department through https://www.bms.com/investors/investor-contacts.html. Copies of the documents filed with the SEC by Celgene are available free of charge on Celgene’s internet website at http://www.celgene.com under the tab “Investors” and under the heading “Financial Information” and subheading “SEC Filings” or by contacting Celgene’s Investor Relations Department at ir@celgene.com.

Cautionary Statement Regarding Forward-Looking Statements
 
This communication contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the research, development and commercialization of pharmaceutical products, Bristol-Myers Squibb’s pending acquisition of Celgene (the “Merger”), and the pending sale of OTEZLA (the “Divestiture,” and together with the Merger, the “Transaction”). These statements may be identified by the fact they use words such as “should,” “could,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” “will” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. One can also identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements are based on historical performance and current expectations and projections about Bristol-Myers Squibb’s and Celgene’s future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond Bristol-Myers Squibb’s and Celgene’s control and could cause Bristol-Myers Squibb’s and Celgene’s future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. Such risks, uncertainties and other matters include, but are not limited to, the completion of the Transaction may not occur on the anticipated terms and timing or at all; a condition to the closing of the Merger may not be satisfied; Bristol-Myers Squibb successfully using proceeds from the Divestiture; the combined company will have substantial indebtedness following the completion of the Transaction; Bristol-Myers Squibb is unable to achieve the synergies and value creation contemplated by the Merger; Bristol-Myers Squibb is unable to promptly and effectively integrate Celgene’s businesses; management’s time and attention is diverted on transaction related issues; disruption from the transaction makes it more difficult to maintain business, contractual and operational relationships; the credit ratings of the combined company decline following the Transaction; legal proceedings are instituted against Bristol-Myers Squibb, Celgene or the combined company; Bristol-Myers Squibb, Celgene or the combined company is unable to retain key personnel; and the announcement or the consummation of the Transaction has a negative effect on the market price of the capital stock of Bristol-Myers Squibb and Celgene or on Bristol-Myers Squibb’s and Celgene’s operating results. No forward-looking statement can be guaranteed.

Forward-looking statements in this communication should be evaluated together with the many risks and uncertainties that affect Bristol-Myers Squibb’s and Celgene’s respective business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol-Myers Squibb’s and Celgene’s respective Annual Reports on Form 10-K for the year ended December 31, 2018, as updated by their subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC. The forward-looking statements included in this communication are made only as of the date of this communication and except as otherwise required by applicable law, neither Bristol-Myers Squibb nor Celgene undertakes any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

Item 9.01
Financial Statements and Exhibits.

(d) Exhibits
 
The following exhibits are included as part of this Current Report on Form 8-K:

Exhibit
No.
  
Description
   
99.1
  
Press Release of Bristol-Myers Squibb Company, dated November 15, 2019.
     
99.2
  
Press Release of Bristol-Myers Squibb Company, dated November 15, 2019.
     
104
  
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

EXHIBIT INDEX

Exhibit
No.
  
Description
   
 
Press Release of Bristol-Myers Squibb Company, dated November 15, 2019.
     
 
Press Release of Bristol-Myers Squibb Company, dated November 15, 2019.
     
104
  
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
BRISTOL-MYERS SQUIBB COMPANY
   
Dated: November 15, 2019
By:
 /s/ Katherine R. Kelly  
 
Name:
Katherine R. Kelly
 
Title:
Corporate Secretary
 

 EX-99.1 2 ex99_1.htm PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY
Exhibit 99.1

Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition

Company Has Now Satisfied All Regulatory Approvals for Celgene Acquisition

Transaction Expected to Close on November 20, 2019

FTC Approves Agreement between Celgene and Amgen to Divest OTEZLA®

NEW YORK—November 15, 2019—Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Federal Trade Commission (FTC) has accepted the proposed consent order in connection with the pending merger of Bristol-Myers Squibb and Celgene Corporation (NASDAQ:CELG), thereby permitting the parties to close the transaction. As announced on August 26, 2019, Celgene entered into an agreement with Amgen (NASDAQ:AMGN) under which Amgen would acquire the global rights to OTEZLA® (apremilast). Bristol-Myers Squibb previously announced the decision to divest OTEZLA in connection with the ongoing regulatory approval process for Bristol-Myers Squibb’s pending merger with Celgene.

Bristol-Myers Squibb has now satisfied all regulatory requirements under the merger agreement to complete the acquisition of Celgene and expects to close the transaction on November 20, 2019. Bristol-Myers Squibb also expects the OTEZLA divestiture to be completed promptly following the closing of the merger.

“Today’s news is an exciting milestone in our company’s history as we look forward to officially combining with Celgene to create a leading biopharma company,” said Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol-Myers Squibb. “Together we will be well positioned to discover, develop and deliver innovative medicines, and to transform the lives of more patients through science.”

Advisors

Morgan Stanley & Co. LLC is serving as financial advisor to Bristol-Myers Squibb and Kirkland & Ellis LLP is serving as Bristol-Myers Squibb’s legal counsel. Arnold & Porter Kaye Scholer LLP is acting as legal counsel on antitrust matters.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.

Important Information for Investors and Stockholders

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectus equivalent document. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

In connection with the proposed transaction between Bristol-Myers Squibb Company (“Bristol-Myers Squibb”) and Celgene Corporation (“Celgene”), on February 1, 2019, Bristol-Myers Squibb filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4, as amended on February 1, 2019 and February 20, 2019, containing a joint proxy statement of Bristol-Myers Squibb and Celgene that also constitutes a prospectus of Bristol-Myers Squibb. The registration statement was declared effective by the SEC on February 22, 2019, Bristol-Myers Squibb and Celgene commenced mailing the definitive joint proxy statement/prospectus to stockholders of Bristol-Myers Squibb and Celgene on or about February 22, 2019, and the special meetings of the stockholders of Bristol-Myers Squibb and Celgene were held on April 12, 2019. INVESTORS AND SECURITY HOLDERS OF BRISTOL-MYERS SQUIBB AND CELGENE ARE URGED TO READ THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the registration statement and the definitive joint proxy statement/prospectus and other documents filed with the SEC by Bristol-Myers Squibb or Celgene through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by Bristol-Myers Squibb are available free of charge on Bristol-Myers Squibb’s internet website at http://www.bms.com under the tab, “Investors” and under the heading “Financial Reporting” and subheading “SEC Filings” or by contacting Bristol-Myers Squibb’s Investor Relations Department through https://www.bms.com/investors/investor-contacts.html. Copies of the documents filed with the SEC by Celgene are available free of charge on Celgene’s internet website at http://www.celgene.com under the tab “Investors” and under the heading “Financial Information” and subheading “SEC Filings” or by contacting Celgene’s Investor Relations Department at ir@celgene.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the research, development and commercialization of pharmaceutical products, Bristol-Myers Squibb’s pending acquisition of Celgene (the “Merger”), and the pending sale of OTEZLA (the “Divestiture,” and together with the Merger, the “Transaction”). These statements may be identified by the fact they use words such as “should,” “could,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” “will” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. One can also identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements are based on historical performance and current expectations and projections about Bristol-Myers Squibb’s and Celgene’s future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond Bristol-Myers Squibb’s and Celgene’s control and could cause Bristol-Myers Squibb’s and Celgene’s future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. Such risks, uncertainties and other matters include, but are not limited to, the completion of the Transaction may not occur on the anticipated terms and timing or at all; a condition to the closing of the Merger may not be satisfied; Bristol-Myers Squibb successfully using proceeds from the Divestiture; the combined company will have substantial indebtedness following the completion of the Transaction; Bristol-Myers Squibb is unable to achieve the synergies and value creation contemplated by the Merger; Bristol-Myers Squibb is unable to promptly and effectively integrate Celgene’s businesses; management’s time and attention is diverted on transaction related issues; disruption from the transaction makes it more difficult to maintain business, contractual and operational relationships; the credit ratings of the combined company decline following the Transaction; legal proceedings are instituted against Bristol-Myers Squibb, Celgene or the combined company; Bristol-Myers Squibb, Celgene or the combined company is unable to retain key personnel; and the announcement or the consummation of the Transaction has a negative effect on the market price of the capital stock of Bristol-Myers Squibb and Celgene or on Bristol-Myers Squibb’s and Celgene’s operating results. No forward-looking statement can be guaranteed.

Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol-Myers Squibb’s and Celgene’s respective business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol-Myers Squibb’s and Celgene’s respective Annual Reports on Form 10-K for the year ended December 31, 2018, as updated by their subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this press release are made only as of the date of this document and except as otherwise required by applicable law, neither Bristol-Myers Squibb nor Celgene undertakes any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

Contacts

Media:
609-252-3345
media@bms.com

Investors:
Tim Power
609-252-7509
Timothy.Power@bms.com

Or

Andy Brimmer / Dan Katcher / Jamie Moser
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449

 EX-99.2 3 ex99_2.htm PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY
Exhibit 99.2

 
Bristol-Myers Squibb Company Announces it Expects No Further Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
 
NEW YORK, November 15, 2019 – Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today that it currently expects there will be no further extension of the expiration date of the offers to exchange (the “Exchange Offers”) notes (the “Celgene Notes”) issued by Celgene Corporation (NASDAQ:CELG) (“Celgene”) for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company (the “Bristol-Myers Squibb Notes”) and cash and the related consent solicitations (the “Consent Solicitations”) being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments (the “Amendments”) to the indentures governing the Celgene Notes. As previously announced, the Exchange Offers and Consent Solicitations are currently scheduled to expire at 5:00 p.m., New York City time, on November 20, 2019 (the “Expiration Date”).
 
The closing of the Merger is expected to occur on November 20, 2019. As a result, Bristol-Myers Squibb currently expects that there will be no further extension of the Expiration Date as it is anticipated that the Merger will be completed on the Expiration Date. The settlement date for the Exchange Offers is expected to occur on November 22, 2019.
 
On the early participation date of May 1, 2019, requisite consents were received and supplemental indentures were executed, eliminating substantially all restrictive covenants and certain events of default and other provisions in each of the indentures governing the Celgene Notes. Such supplemental indentures will become operative upon the settlement date of the Exchange Offers.
 
The Exchange Offers and Consent Solicitations are being made pursuant to the terms and subject to the conditions set forth in the confidential offering memorandum and consent solicitation statement dated April 17, 2019 and the related letter of transmittal hereby, each as amended by the press releases dated May 1, 2019, May 24, 2019, June 28, 2019, September 23, 2019, October 8, 2019, October 18, 2019, October 30, 2019, November 1, 2019, November 5, 2019, November 7, 2019, November 12, 2019 and November 15, 2019, and are conditioned upon the closing of Bristol-Myers Squibb’s acquisition of Celgene (the “Merger”), which condition may not be waived by Bristol-Myers Squibb, and certain other conditions that may be waived by Bristol-Myers Squibb.
 
Documents relating to the Exchange Offers and Consent Solicitations will only be distributed to eligible holders of Celgene Notes who complete and return an eligibility form confirming that they are either a “qualified institutional buyer” under Rule 144A or not a “U.S. person” and outside the United States under Regulation S for purposes of applicable securities laws. Except as amended by the press releases dated May 1, 2019, May 24, 2019, June 28, 2019, September 23, 2019, October 8, 2019, October 18, 2019, October 30, 2019, November 1, 2019, November 5, 2019, November 7, 2019, November 12, 2019 and November 15, 2019, the complete terms and conditions of the Exchange Offers and Consent Solicitations are described in the confidential offering memorandum and consent solicitation statement dated April 17, 2019 and the related letter of transmittal, copies of which may be obtained by contacting Global Bondholder Services Corporation, the exchange agent and information agent in connection with the Exchange Offers and Consent Solicitations, at (866) 470 3900 (U.S. toll-free) or (212) 430 3774 (banks and brokers). The eligibility form is available electronically at: https://gbsc-usa.com/eligibility/bristol-myers.
 
1
This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, or the solicitation of tenders or consents with respect to, any security. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation or sale would be unlawful. The Exchange Offers and Consent Solicitations are being made solely pursuant to the confidential offering memorandum and consent solicitation statement dated April 17, 2019, as amended by the press releases dated May 1, 2019, May 24, 2019, June 28, 2019, September 23, 2019, October 8, 2019, October 18, 2019, October 30, 2019, November 1, 2019, November 5, 2019, November 7, 2019, November 12, 2019 and November 15, 2019, and the related letter of transmittal and only to such persons and in such jurisdictions as are permitted under applicable law.

The Bristol-Myers Squibb Notes offered in the Exchange Offers have not been registered under the Securities Act of 1933, as amended, or any state securities laws. Therefore, the Bristol-Myers Squibb Notes may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933, as amended, and any applicable state securities laws.

Cautionary Statement Regarding Forward-Looking Statements
 
This press release contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the research, development and commercialization of pharmaceutical products, Bristol-Myers Squibb’s pending acquisition of Celgene (the “Merger”), and the pending sale of OTEZLA (the “Divestiture,” and together with the Merger, the “Transaction”). These statements may be identified by the fact they use words such as “should,” “could,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” “will” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. One can also identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements are based on historical performance and current expectations and projections about Bristol-Myers Squibb’s and Celgene’s future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond Bristol-Myers Squibb’s and Celgene’s control and could cause Bristol-Myers Squibb’s and Celgene’s future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. Such risks, uncertainties and other matters include, but are not limited to, the completion of the Transaction may not occur on the anticipated terms and timing or at all; a condition to the closing of the Merger may not be satisfied; Bristol-Myers Squibb successfully using proceeds from the Divestiture; the combined company will have substantial indebtedness following the completion of the Transaction; Bristol-Myers Squibb is unable to achieve the synergies and value creation contemplated by the Merger; Bristol-Myers Squibb is unable to promptly and effectively integrate Celgene’s businesses; management’s time and attention is diverted on transaction related issues; disruption from the transaction makes it more difficult to maintain business, contractual and operational relationships; the credit ratings of the combined company decline following the Transaction; legal proceedings are instituted against Bristol-Myers Squibb, Celgene or the combined company; Bristol-Myers Squibb, Celgene or the combined company is unable to retain key personnel; and the announcement or the consummation of the Transaction has a negative effect on the market price of the capital stock of Bristol-Myers Squibb and Celgene or on Bristol-Myers Squibb’s and Celgene’s operating results. No forward-looking statement can be guaranteed.

2
Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol-Myers Squibb’s and Celgene’s respective business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol-Myers Squibb’s and Celgene’s respective Annual Reports on Form 10-K for the year ended December 31, 2018, as updated by their subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this press release are made only as of the date of this press release and except as otherwise required by applicable law, neither Bristol-Myers Squibb nor Celgene undertakes any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

Contacts

Media:
media@bms.com
609-252-3345

Investors:
Tim Power
609-252-7509
timothy.power@bms.com


3

 EX-101.SCH 4 bmy-20191115.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 bmy-20191115_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 bmy-20191115_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Amendment Flag City Area Code Entity Address, City or Town Entity Address, Country Document Period End Date Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Listings [Table] Local Phone Number Entity Address, Postal Zip Code Entity Address, State or Province Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Entity Listings [Line Items] Entity Registrant Name Entity Central Index Key Entity Tax Identification Number Document Fiscal Year Focus Document Fiscal Period Focus Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity File Number Entity Emerging Growth Company Class of Stock [Domain] Common Stock [Member] Class of Stock [Axis] 1.750% Notes due 2035 [Member] 1.000% Notes due 2025 [Member] EX-101.PRE 7 bmy-20191115_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 image00005.jpg begin 644 image00005.jpg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end XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 4 97 1 false 3 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://bms.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports form8k.htm bmy-20191115.xsd bmy-20191115_def.xml bmy-20191115_lab.xml bmy-20191115_pre.xml ex99_1.htm ex99_2.htm http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end JSON 11 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 4, "dts": { "definitionLink": { "local": [ "bmy-20191115_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "form8k.htm" ] }, "labelLink": { "local": [ "bmy-20191115_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "bmy-20191115_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "bmy-20191115.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 37, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 2, "memberStandard": 1, "nsprefix": "bmy", "nsuri": "http://bms.com/20191115", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "form8k.htm", "contextRef": "c20191115to20191115", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://bms.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "form8k.htm", "contextRef": "c20191115to20191115", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "bmy_One000NotesDue2025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "1.000% Notes due 2025 [Member]" } } }, "localname": "One000NotesDue2025Member", "nsuri": "http://bms.com/20191115", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "bmy_One750NotesDue2035Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "1.750% Notes due 2035 [Member]" } } }, "localname": "One750NotesDue2035Member", "nsuri": "http://bms.com/20191115", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 12 form8k_htm.xml IDEA: XBRL DOCUMENT 0000014272 2019-11-15 2019-11-15 0000014272 us-gaap:CommonStockMember 2019-11-15 2019-11-15 0000014272 bmy:One000NotesDue2025Member 2019-11-15 2019-11-15 0000014272 bmy:One750NotesDue2035Member 2019-11-15 2019-11-15 false 0000014272 8-K 2019-11-15 BRISTOL-MYERS SQUIBB COMPANY DE 001-01136 22-0790350 430 East 29th Street 14th Floor New York NY 10016 212 546-4000 true false false false Common Stock, $0.10 Par Value BMY NYSE 1.000% Notes due 2025 BMY 25 NYSE 1.750% Notes due 2035 BMY 35 NYSE false ZIP 13 0001140361-19-020720-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-19-020720-xbrl.zip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end XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R1.htm IDEA: XBRL DOCUMENT v3.19.3
Document and Entity Information
Nov. 15, 2019
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 15, 2019
Entity Registrant Name BRISTOL-MYERS SQUIBB COMPANY
Entity Incorporation, State or Country Code DE
Entity File Number 001-01136
Entity Tax Identification Number 22-0790350
Entity Address, Address Line One 430 East 29th Street
Entity Address, Address Line Two 14th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10016
City Area Code 212
Local Phone Number 546-4000
Written Communications true
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000014272
Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common Stock, $0.10 Par Value
Trading Symbol BMY
Security Exchange Name NYSE
1.000% Notes due 2025 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.000% Notes due 2025
Trading Symbol BMY 25
Security Exchange Name NYSE
1.750% Notes due 2035 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.750% Notes due 2035
Trading Symbol BMY 35
Security Exchange Name NYSE
XML 17 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}